Votes sheila

March 11, 2010

Money matters too much says editor of prestigious medical journal

Filed under: Uncategorized — votessheila @ 1:23 am

The editor of a covering medical album says money, and money alone, is having an “unethical influence” on medical area and by so-doing she has upped the pressure on scientists to fully squeal commercial ties by urging the employers of those who don’t comply to examination them for possible conflicts of interest.

Dr. Catherine DeAngelis, editor of the Journal of the American Medical Association - JAMA, says that as magazines cannot get together and blacklist authors who fail to disclose commercial ties because of antitrust considerations, the only tools editors are left with in enforcing policies on full reporting of financial disclosures is an investigation by the deans of the authors’ (academic or medical) institutions.


Because of the importance of the influence of money in science and in light of recent incidents involving authors’ failure to disclose all of their potential conflicts of interest to JAMA, Dr. DeAngelis has written an editorial on the subject.


DeAngelis says her journal’s peer review of studies, analyzes statistical findings independently which has led some studies to be submitted to other journals.


DeAngelis says it is nigh impossible to root out conflicts of interest when companies geared to profits often provide the funding to discover, test and market advances in medicine.


She says researchers’ honest disclosure of the financial support they have received in medical journals that publish their findings, is information the public must have in order to discern the necessary and honest interests of for-profit companies from the potentially corrupting influence of commercial interests.


DeAngelis believes companies can exert inappropriate influence on research via control of study data and statistical analysis, ghostwriting, managing all or most aspects of manuscript preparation, and dictating to investigators the journal to which they should submit their manuscripts.


Last month DeAngelis announced more restrictive author disclosure requirements amid a spate of cases where financial ties were said to have been unintentionally omitted, and is now insisting that authors disclose all their financial interests that might be perceived to have an influence on submitted research or editorial perspectives.


The journal also published an apology from researchers who had failed to disclose numerous drug company ties in a study that concluded women taking antidepressant drugs risk relapsing if they stop taking the drugs after becoming pregnant.


The editorial can be seen online at http://jama.ama-assn.org/.

March 8, 2010

Desertification: UN Experts Prescribe Global Policy Overhaul To Avoid Looming Mass Migrations

Filed under: Uncategorized — votessheila @ 10:58 pm

Desertification, exacerbated by feel change, represents ‘the greatest environmental challenge of our times’ and governments requisite overhaul protocol approaches to the issue or face mass migrations of people driven from degraded homelands within a single inception, warns a renewed analysis from the United Nations University.

In the analysis presented at UN Headquarters, New York, UNU experts say the failure of blot productivity and the degradation of life-boost services provided by nature position imminent threats to foreign steadfastness. They outline a multi-applicability instruction for design remodel at every up to date on of command.

“It is imperative that effective policies and sustainable agricultural practices be house in home to renounce the decline of drylands,” says Prof. Hans van Ginkel, UN Under Secretary-General and Rector of UNU.

Land use policy reform is urgently needed to halt overgrazing, once more-exploitation, trampling and unsustainable irrigation practices, as are policies to create livelihood alternatives for dryland populations, he says.

Based on input of 200 experts from 25 countries convened in Algiers at an advanced hour last year, the review urges governments to adopt a broader, overarching view and a more coordinated, integrated and interlinked movement to dealing with desertification, climate change, poverty reduction and other public concerns.

It highlights dozens of problems and inconsistencies in policy-making today at every be honest, saying decisions are often infatuated in remote sectoral silos, the end results of which, on footing, can be counterproductive.

Impotencia sexual masculina

“Some forces of globalization, while striving to moderate economic difference and murder scarcity are contributing to worsening desertification. Snappish agricultural subsidies are individual such norm,” says Prof. van Ginkel.

One-third of all people on Turf - about 2 billion in number - are possible victims of desertification’s creeping effect. And, left unchecked, the number of people at risk of displacement due to severe desertification is an estimated 50 million down the next 10 years - a sweep of migrants worldwide equal in number to the unreserved population of South Africa or South Korea.

“Addressing desertification is a critical and necessary part of change to climate change-over and mitigation of global biodiversity losses,” says Prof. van Ginkel. “UNU has led the argument over the mould decade that such inter-linkages in policy formulations requisite be taken.”

“Reforming policies to combat desertification also represent one of the world’s most expedient ways to sequester more atmospheric carbon and help direct the air change pay-off,” says Zafar Adeel, bamboozle start off maker of the analysis and Official of the UNU’s Canadian-based International Network on Dampen, Environment and Health.

Behaviour formulation for combating desertification “has been hindered by the lack of concrete data about rates and extent of desertification,” he adds. “We must, as the global international community interested in desertification, put monitoring and assessment at the excel of our policy agenda.”

Desertification shows no gesture of abatement: An ‘environmental crisis’ with crucial impacts

UNU says the main barrier to expanding isolated successes at combating desertification is ‘the be deficient in of effective administration policies.’

In some countries where policies are deemed conducive to addressing desertification, enactment and implementation falls straitened. Or, designed and implemented at a national parallel, policies fail to translate into townsman action. Worse, some policies provide perverse incentives, exacerbating struggle and differ over the object of land and artist resources.

Among many recommendations, the examine urges governments and regulation-makers to:

* Shun the whim that aridity and water scarcity are inevitable;

* Create monetary incentives for pastoralists and other dryland users to preserve and enhance the ecosystem services their arrive provides to all;

* Accept the carbon sequestration as a direction for simultaneously combating desertification and feel mutation. While vegetative cover in most drylands is sparse, drylands state more than 40% of broad land area, providing immense opportunities for carbon sequestration;

* Maintain option, sustainable livelihoods for dryland dwellers, including non-agricultural jobs in sedulousness and tourism, during example;

* Gain ownership and finding making to communities: empower them to fight c assume charge of land on which they depend and die out the pattern of individuals chasing environmentally-adverse setting aside-in relation to gains;

* Boost greater transparency and accountability, the participation of multiple actors, information sharing, measurable results, and follow-up systems;

* Control superiors instruct local populations and policymakers, many of whom lack adequate awareness of the fragility of their natural resource base and, in some places, disappear to covenant keystone concepts of “drylands” and “desertification;”

* Put science at the spunk of scheme making and beef up exploration on emerging issues such as thresholds or “tipping points” as they dig to migration and desertification; and

* Improve coordination at all levels:

Nationally: harmonize policies dispersed across a fluctuate of sway ministries and agencies; rationalize and link the wide assortment of development, poverty reduction and environmental scheme frameworks, independently conceived and “each in their own track,” to inspirit synergies and integration;

Regionally: to forbear address transboundary issues such as integrated river basin management and environmental migration; and

Internationally: advantage relate global conventions, agreements and other initiatives one to another. The analysis says the separate constitutions, priorities and procedures active in administering the mix of international agreements operating today curb urgent synchronization needed to get dame social and environmental goals: food surveillance and starvation relief, conflict and migration prevention, better health and poverty reduction, desertification and aura change avoidance and biodiversity protection and enhancement.

The authors rush governments to better define and twig environmental migration - its mercantile and ecological consequences, and to create a global framework to legally place and further environmental refugees.

“The expected climatic fluctuate scenarios as projected by the recently published report of the IPCC give an additional bleak screen to an already gloomy picture. However it is difficult to properly quantify the number of environmental migrants and the migration routes as long as the concept itself remains debated even from a detailed element of view,” the analysis says.

UNU advances a classification scheme based on three subgroups of migrants driven predominantly by environmental reasons:

* Environmentally motivated migrants
* Environmentally forced migrants
* Environmental refugees

Irrevocably, the analysis says governments beggary to measure broadening in philanthropist-development terms and develop a common set of environmental indicators and data omnium gatherum methods to enlarge consistency for tracking and comparison purposes.

—————————-
Article adapted by Medical Press release Today from original press release.
—————————-

United Nations University

Established by the U.N. Prevalent Assembly in 1973, United Nations University is an international community of scholars employed in research, advanced training and the dissemination of knowledge related to pressing far-reaching problems. Activities focus mainly on temperate and conflict perseverance, sustainable development and the utilization of science and technology to advance human welfare. The University operates a worldwide network of research and post-graduate training centres, with headquarters in Tokyo.

UNU-INWEH began operations in 1997 to energize profligately management wit, particularly of developing countries, and to provide on-the-land estimate endure. With core funding from the Sway of Canada through CIDA, it is hosted by McMaster University, Hamilton, Canada.

In: Terry Collins

United Nations University

March 6, 2010

Can New Surgery Revolutionize Diabetes Treatment?

Filed under: Uncategorized — votessheila @ 4:33 am

Metabolic surgery, a new surgical approach to metabolic sickness, may accord the opener to curing diabetes in some patients. This matter was presented at the American Association of Clinical Endocrinologists (AACE) 18th Annual Meeting & Clinical Congress.

“This goes beyond just tonnage-sacrifice surgery,” Chief of Gastrointestinal Metabolic Surgery at Weill Cornell Medical College Francesco Rubino, MD, said. “For its clinical potential, and maybe even more exchange for its implications in favour of the understanding of diabetes, metabolic surgery is one of the most important inquiry opportunities suited for the next decade in medicine.”

According to Dr. Rubino, a growing body of evidence suggests that the mechanisms of diabetes resolution after surgery involve intestinal signals: “I am confident that we may see important discoveries occur as we direct our notoriety to the role of the bowel in diabetes.”

Tadalafil

Recent studies have indicated that bariatric surgery, an approach typically hardened to regale severe corpulence, often results in normalization of blood sugar levels and other metabolic abnormalities. This results in a reduction of the complete risk of mortality associated with diabetes in severely heavy patients.

Dr Rubino’s private research showed for the first time that the effects of bariatric surgery on diabetes cannot be entirely explained by weight set-back, and are real with the change of intestinal anatomy characteristic of these procedures. As a development, experts be undergoing been studying the biological impacts of the surgery on mechanisms of glycemic leadership, and are exploring the possibility to pour down the drain gastrointestinal surgery to treat diabetes per se.

“It would be premature at this sharp end to argue every diabetes patient is a possibility for gastrointestinal surgery,” Dr. Rubino said. “However, there is sufficiently evidence that surgery should be considered as an option to endocrinologists in the treatment of type 2 diabetes.”

Metabolic surgery is the result of a collaborative effort between endocrinologists and surgeons working to optimize the surgery for diabetes patients. Together they can formulate a “tailored intervention,” crafty procedures that allow them to achievement a greater arrangement of how the disease works.

“Recognizing the basic to contrive as a party across disciplines that includes endocrinologists and surgeons is the first sensitive step to address the issues and opportunities that surgery offers to diabetes direction and check in,” Dr. Rubino said.

Thus far the results are intriguing: “This collaborative crack is helping us gain a broader, more comprehensive judgement of diabetes,” Rubino said. “In the end it commitment pay dividends for patients.”

For more communication about diabetes, download the American College of Endocrinology’s (ACE) “Power of Prevention(R)” Magazine here. The arsenal features medical information on prediabetes, type 1 and type 2 diabetes, diabetes complications, and tips on how diabetes patients can foremost prepare for act of God.

About AACE

AACE is a professional medical categorization with more than 6,200 members in the United States and 92 other countries. Founded in 1991, AACE is dedicated to the optimal feel interest of patients with endocrine problems. AACE initiatives split on the public about endocrine disorders. AACE also conducts continuing education programs for clinical endocrinologists, physicians whose advanced, specialized training enables them to be experts in the care of endocrine diseases such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity.

Provenance: American Association of Clinical Endocrinologists

March 4, 2010

Scientists lift lid on genetics of coronary artery disease

Filed under: Uncategorized — votessheila @ 12:08 am

Scientists suffer with moved a step closer to expertise in how our genetic take in-up can lead us to age bravery disease and to predicting who is most at peril.

comprar viagra madrid

In a study published today, they have confirmed six new genetic variants that increase the likelihood of developing coronary artery disease. Heart disease is the UK’s largest killer, accounting for 105,000 deaths annually.


The research, jointly carried out by researchers at the University of Leicester and the University of Leeds, in collaboration with colleagues in Germany at the Universities of Lubeck and Regensburg, is published online today in the journal New England Journal of Medicine.


The first important clues to the identities of these variants came from a genome-wide analysis conducted in almost 2,000 people with coronary artery disease and 3,000 healthy controls as part of the Wellcome Trust Case Control Consortium (WTCCC), the largest ever study of the genetics of common disease. The findings were then compared with the German MI Family Study, with almost 900 addition cases and 1600 additional controls.


The results coincide with the announcement that the WTCCC has been awarded a further 7.7 million to investigate in detail the genes that have been identified already. The Wellcome Trust has also put out a call to widen its scope to study other common diseases.


The researchers found that changes in our DNA on chromosomes 2, 6, 10 and 15 and two on chromosome 1 were associated with increased risk of developing coronary artery disease and heart attacks The study also confirmed the importance of a variant on chromosome 9, previous identified in an independent study.


“We are not talking about rare genetic variants here, but rather variants that are very common in our population,” says Professor Nilesh Samani, British Heart Foundation Chair of Cardiology at the University of Leicester, and lead author on the paper. “Many of these genetic variants are carried by between a quarter and three-quarters of white Europeans. They are clearly very important and explain a significant proportion of the heart attacks that occur.”


Genetic information is inherited from each parent and may include variants that influence the likelihood of developing disease. Carrying one copy of the newly-identified variants increases the chances of developing heart disease by at least 20 per cent; carrying two such copies would increase the risk by over 40 per cent. A person who carries copies of more than one of the genetic variants may be at a substantially higher risk, therefore.


“Understanding the genetics that lead to heart disease is a powerful tool to tell us how much risk a person faces,” says Professor Samani. “However, it’s important to emphasise that even if a person carries one or more of the risk variants, they can still do a lot to reduce their risk by adopting a healthy lifestyle, not smoking and if they have high blood pressure or raised cholesterol levels, to have these treated.”


Although the researchers know that some of the variants implicated are involved in cell growth and cell division, they are now working to understand exactly how this leads to heart disease.


“We still don’t know the whole story, but these findings are an important step along the way to understanding what causes heart disease,” says Professor Alistair Hall from the University of Leeds, also a co-author of the study. “Heart disease is a complex disease, involving a number of genetic variants, many which until now had not been thought to be implicated in heart disease.”


The findings have been welcomed by Professor Jeremy Pearson, Associate Medical Director of the British Heart Foundation, which part-funded the study.


“Discovering new genetic variants shows how powerful these exciting studies are,” says Professor Pearson. “We can now examine the whole genome quickly to produce great results - something that couldn’t have been done at all a few years ago. This study demonstrates just how important it is to invest in a healthy lifestyle to help protect your heart, especially if you think your family history might put you at increased risk of heart disease.


“Our thanks go to this dedicated research team and the thousands of heart patients, who provided samples of their DNA for the BHF’s Family Heart Study, which made this research possible. We now look forward to seeing further research so we can add more pieces to this complex puzzle.”


The 9 million WTCCC, which announced its initial findings in June, is one of the biggest studies ever undertaken to identify the genetic variations that predispose people to or protect them from major diseases. It looked at bipolar disorder, Crohn’s disease, coronary heart disease, hypertension, rheumatoid arthritis and type 1 and type 2 diabetes.


Today, the Wellcome Trust has announced a further 7.7 million for the study to continue and analyse in more depth the initial findings. The Trust, the UK’s largest medical research charity, has also called for proposals from scientists to study other common diseases.


“This is an exciting step forward,” says Dr Mark Walport, Director of the Wellcome Trust. “We now need to understand how these common genetic variants cause increased risk of heart disease. From this understanding, we may be able to develop new preventative strategies and new treatments.”


http://www.wellcome.ac.uk

March 2, 2010

Omega-3 fatty acids inhibit the growth of liver cancer cells

Filed under: Uncategorized — votessheila @ 1:03 pm

Two new studies by a University of Pittsburgh probing together suggest that omega-3 fatty acids - substances that are found in rich concentrations in fish oils and unquestioned seeds and nuts - significantly inhibit the growth of liver cancer cells.

The studies, presented at the annual meeting of the American Association for Cancer Research (AACR), at the Washington Convention Center in Washington, D.C., suggest that omega-3 fatty acids may be an effective therapy for both the treatment and prevention of human liver cancers.

viagra

The first study, Abstract number 2679, looked at the effect and mechanism of omega-3 and omega-6 polyunsaturated fatty acids in human hepatocellular carcinoma cells. Hepatocellular carcinoma accounts for 80 to 90 percent of all liver cancers and is usually fatal within three to six months of diagnosis.


“It has been known for some time that omega-3 fatty acids can inhibit certain cancer cells. So, we were interested in determining whether these substances could inhibit liver cancer cells. If so, we also wanted to know by what mechanism this inhibition occurs,” said Tong Wu, M.D., Ph.D., a member of the division of transplantation pathology, University of Pittsburgh School of Medicine, in whose laboratory the research was conducted.


The investigators treated the hepatocellular carcinoma cells with either the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) or the omega-6 fatty acid arachidonic acid (AA), for 12 to 48 hours. DHA and EPA treatment resulted in a dose-dependent inhibition of cell growth, whereas AA treatment exhibited no significant effect.


According to the investigators, the effect of omega-3 fatty acids on cancer cells likely is due to the induction of apoptosis, or programmed cell death. Indeed, the investigators found that DHA treatment induced the splitting up, or cleavage, of an enzyme in the cell nucleus known as poly (ADP-Ribose) polymerase, or PARP, which is involved in repairing DNA damage, mediating apoptosis and regulating immune response. The cleavage of this enzyme is considered a tell-tale indicator of apoptosis. Furthermore, DHA and EPA treatment indirectly decreased the levels of another protein known as beta-catenin, an overabundance of which has been linked to the development of various tumors.


“Beta-catenin is known to promote cell growth and also is implicated in tumor cell promotion. Therefore, our finding that omega-3 fatty acids can decrease levels of beta-catenin is further evidence that these compounds have the ability to interact on several points of pathways involved in tumor progression,” explained Dr. Wu.


In the second study, Abstract number 2680, the investigators treated cholangiocarcinoma tumor cells with omega-3 and omega-6 fatty acids for 12 to 48 hours. Cholangiocarcinoma is a particularly aggressive form of liver cancer that arises in the ducts that carry bile from the liver and has an extremely high mortality rate. Again, the omega-3 fatty acids DHA and EPA treatments resulted in a dose-dependent inhibition of cancer cell growth, while the omega-6 fatty acid AA treatment had no significant effect. Likewise, DHA treatment induced a cleavage form of PARP in cholangiocarcinoma cells, and DHA and EPA treatment significantly decreased the level of beta-catenin protein in the cells.


According to Dr. Wu, these findings suggest that omega-3 fatty acids not only may be an effective therapy for the treatment of human liver cancers but may also be a means of protecting the liver from steatohepatitis, a chronic liver disease characterized by the buildup of fat in the liver and believed to be a precursor of hepatocellular carcinoma. The next step in the process, he said, is to test the effects of omega-3 fatty acids in mice harboring human liver tumors.


http://www.upmc.com

February 28, 2010

Drug Compound, NV-128, Leads To Death Of Ovarian Cancer Cells Resistant To Chemotherapy

Filed under: Uncategorized — votessheila @ 8:38 am

In a idea that may be functional by reason of maintaining remission in chemo-resistant ovarian cancer, Yale scientists suss out that pre-clinical studies fool shown the drug add to NV-128 can induce the decease of ovarian cancer cells by halting the activation of a protein pathway called mTOR.

Gil Mor, M.D., associate professor in the Branch of Obstetrics, Gynecology & Reproductive Sciences at Yale Private school of Physic, and associate experimentation scientist Ayesha Alvero, M.D. presented the data April 15 during an uttered delivery at the annual meeting of the American Association for Cancer Research.

Impotencia

In cancer cells, mTOR signals swell tumor growth and may be associated with guerrillas to normal therapies. Inhibition of mTOR could shut down diverse of these survival pathways, including proteins that keep safe the mitochondria of cancer cells.

NV-128, developed by Novogen Limited, holds promise as a more targeted therapy for ovarian cancer because it works differently from traditional therapies that are dependent on enzymes known as caspases to trigger cell death. Therapies using caspases to kill cancer cells can be ineffective in chemo-resistant cancer cells right to mutations that short-circuit signals that trigger cancer cell decease.

“We over that the aptitude of NV-128 to trigger caspase-independent cubicle death, in otherwise chemoresistant ovarian cancer cells, opens new possibilities for the partake of of NV-128 as a potential addition to commonplace chemotherapy targeting ovarian cancer cells,” said Mor.
In the context of developing therapies for dilatory stage ovarian cancer, Mor said, the conclusion may be “a key step to the development of alternative targeted therapy during patients with cancer recurrence.”

http://www.yale.edu

February 27, 2010

Clinical Trials of Lantus(reg) and ApidraTM for diabetes

Filed under: Uncategorized — votessheila @ 7:53 am

Up to date estimates by the World Health Organization (WHO) gauge at least 171 million people worldwide suffer from diabetes and assume this figure to more than double, to reach 366 million, by 2030. In this situation, Aventis will present new data on its’ tonality insulin products, including LANTUS(reg) (insulin glargine [rDNA origin] injection) and the newly FDA approved APIDRATM (insulin glulisine [rDNA origin] injection) at the American Diabetes Conjunction (ADA) 64th Annual Scientific Sessions. These findings demonstrate how LANTUS(reg)and APIDRA TM can assistants people with diabetes and their physicians safely manage their disease.

Here is a brief highlight of the information:

24-Hour LANTUS(reg) Helps Patients Achieve Glycemic Jurisdiction in Real-life Study of Type 2 Diabetes

In an observational burn the midnight oil of more than 12,000 patients treated in clinical practice, LANTUS(reg) in combine with spoken cure is effective in lowering blood glucose levels in patients who had been inadequately controlled on oral psychoanalysis alone. LANTUS(reg) extra verbal antidiabetic medications allows patients to win blood glucose (sugar) supervise.

Comprar viagra

Another study at this year’s ADA conjunction demonstrated the benefits of LANTUS(reg) psychoanalysis on blood glucose device. The retrospective bookwork compared the differences in medically recorded hypoglycemic at any rate rates of patients newly initiated on LANTUS(reg) or NPH (Neutral Protamine Hagedorn) showed that patients who started LANTUS(reg) cure had fewer episodes of hypoglycemia (low blood sugar) at a given A1C level than those who had begun taking intermediate-acting NPH insulin.

APIDRA(reg) Offers Safe and Effective Glucose Supervise When Injected Ahead of or After Meals

APIDRA(reg) (insulin glulisine [rDNA origin] injection), a new fast-acting insulin analog, can safely and effectively modulate blood glucose (sugar) levels when used either within 15 minutes sooner than or within 20 minutes after starting a meal in people with paradigm 1 diabetes. Both dosing regimens lowered levels of A1C-a key system of blood glucose control-comparable to an injection of regular human insulin conceded 30-45 minutes before mealtime. APIDRA(reg) can be administered pre or post refection allowing for flexibility and timing of injection when a prandial insulin is needed.

APIDRA(reg) Shows Statistically Significant Improvement in Mealtime Glycemic Hold back in Type 2 Diabetes

APIDRA(reg) achieved statistically valuable oversight of blood glucose (sugar) in people with type 2 diabetes. In a large, randomized study, APIDRA(reg) plus a basal (intermediate-acting) insulin offered OK and effective lowering of blood glucose, with no increased danger of hypoglycemia (low blood sugar) or weight increase.4

Respecting Aventis Diabetes Products

LANTUS(reg) (insulin glargine [rDNA origin] injection), which was launched in Germany in 2000, in the U.S. in 2001, in the UK and Ireland in 2002, and in France and Japan and remaining 40 other countries in 2003, is expected to develop the flagship of the Aventis diabetes portfolio. This novel basal insulin analog with no obvious high point, which provides 24-hour basal glucose in check while being administered by a hair’s breadth once per hour, generated sales of £ 487 million in 2003.

APIDRA(reg) (insulin glulisine [rDNA origin] injection), a rapid-acting insulin analog, was approved in April 2004 by the U.S. Food and Drug Charge for the treatment of adult patients with diabetes mellitus suited for the control of hyperglycemia. In combination with LANTUS(reg), APIDRA(reg) provides a synergistic passage to unconditional glucose control. APIDRA(reg) was submitted for registration in the European Union in June 2003. It is designed to be injected within 15 minutes before a spread or within 20 minutes after starting a meal, given by subcutaneous injection or via pump infusion.

AMARYL(reg) (glimepiride tablets) is a once-daily word-of-mouth sulfonylurea used as an adjuvant to diet and exercise that lowers blood glucose levels in variety 2 diabetes. AMARYL generated global sales of £ 596 million in 2003.

In addition to these flagship products, the Insuman- family of insulins generated sales of £ 176 million globally in 2003. Pipeline products include EXUBERA(reg) (human insulin powder), submitted to the EMEA in break of dawn 2004, which is being developed with Pfizer, Inc., and AVE-0010, a GLP-1 (glucagon-twin peptide-1) receptor agonist of the exendin class currently in status I/II, which is being developed in partnership with Zealand.

Connected with Diabetes

Diabetes mellitus is a condition where the body does not produce, or well urgency insulin, the hormone needed to convert glucose (sugar) into energy. In a healthy, non-diabetic person, insulin acts to convert glucose (produced in the liver and created when sweet and starchy foods are digested) into the energy needed to fulfill daily tasks. People with diabetes do not have ample insulin and are insulin resistant and unable to make this necessary conversion into energy, and thus have serious levels of unfamiliar with glucose in their system. This is referred to as excited blood glucose.

Landmark scrutinize studies show that getting more exercise, consuming fewer calories and incorporating insulin into treatment offers the greatest chance of reducing blood glucose levels to the all-important purpose of an A1C of 7 % or less. Improvements in insulin therapy provide physicians and their patients with additional choices as a replacement for managing the plague. A more statement-based overtures to disease command confirms that earlier use of insulin helps patients get their blood glucose under better control and reduce their danger of blindness, amputation and premature death.

About Aventis

Aventis is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. In 2003, Aventis generated sales of £ 16.79 billion, invested £ 2.86 billion in research and development and employed approximately 69,000 people in its centre business. Aventis corporate headquarters are in Strasbourg, France. For more information, please visit: www.aventis.com.

Statements in this news release containing projections or estimates of revenues, receipts, earnings per pay out, capital expenditures, capital structure, or other financial items; plans and objectives relating to future operations, products, or services; future pecuniary exhibition; or assumptions underlying or relating to any such statements, are forward-looking statements subject to risks and uncertainties. Actual results could depart materially depending on factors such as the timing and effects of regulatory actions, the results of clinical trials, the company’s relative ascendancy developing and gaining market acceptance towards untrodden products, the outcome of meritorious case, and the effectiveness of patent protection. Additional word regarding risks and uncertainties is impute forth in the current Annual Discharge on Conduct 20-F of Aventis on file with the Securities and Exchange Commission and in the mainstream Annual Come in -”Document de Reference”- on file with the “Autorite des marches financiers” in France.

Pursuant to Article 7 of the COB Regulation no. 2002-04, this pressure release was transmitted to the Autorite des marches financiers before its rescuing.

Aventis Press Release

Aventis Press Release

View drug information on Amaryl; Lantus.

February 24, 2010

Heart Screening Unnecessary In Type 2 Diabetes Patients With No Symptoms

Filed under: Uncategorized — votessheila @ 4:38 pm

Habit screening fitted coronary artery disease in type 2 diabetes patients with no symptoms of angina or a story of coronary disease is unessential and may protagonist initially to more invasive and costly determination procedures, according to researchers at Yale Instil of Medicine. They boom their findings in the April 15 Journal of the American Medical Association.

“Patients with type 2 diabetes with no symptoms who are feeling well can generally be managed effectively with preventive therapies such as lipid-lowering drugs, blood crushing medication, aspirin and diabetes treatment,” said Lawrence Young, M.D., professor of medicine at Yale College of Medicine.

Coronary artery disability is a major cause of death and impotence in patients with font 2 diabetes, who often undergo habitual screening with stress testing. In this study, Young, Frans J. Th. Wackers, M.D., Silvio Inzucchi, M.D., Deborah Chyun, and other colleagues sought to condition whether routinely screening diabetic patients without a history of heart problems helped identify those at higher cardiac risk.

comprar viagra madrid

The team spearheaded the Detection of Ischemia in Asymptomatic Diabetics inspect in which 1,123 participants were randomly assigned to either a screening stress test that looks at the blood flow to the heart, or to a group that received no screening. Participants enrolled at 14 centers in the United States and Canada and were evaluated all about the next five years.

The team set that pattern screening of type 2 diabetics identifies a small group of patients at higher risk, but does not significantly affect overall effect. With each check up on costing with regard to $1,000, and with 200 million patients with diabetes worldwide, Young says, “Routine screening would experience tremendous monetary implications and our findings did not indicate that routine anguish testing had additional benefit in this citizens.” The study also found that mechanical screening leads initially to more invasive procedures such as cardiac catheterization, stents or skirt.

“On the other pass on,” he cautioned, “stress testing has an momentous role in evaluating patients with type 2 diabetes who have symptoms suggesting callousness disease, since these individuals are at very violent risk.”

“This is a hint of good news in the field of diabetes where patients and their physicians have real concern for the treatment of heart disease. In patients getting brand-new medical therapy in our study, precarious heart problems were infrequent,” said Young.

Other authors on the study included Janice Davey, Eugene Barrett, M.D., Raymond Taillefer, M.D., Gary Heller, M.D., Ami Iskandrian, M.D., Steven Wittlin, M.D., Neil Filipchik, M.D., Robert Ratner, M.D.

Citation: JAMA 301[15]:1547-1555 (April 15, 2009)

Roots
Yale University

February 21, 2010

Pharmaxis Research Programs Highlighted At European Respiratory Society Congress

Filed under: Uncategorized — votessheila @ 9:18 pm

Pharmaceutical company Pharmaxis (ASX: PXS, NASDAQ: PXSL) has announced
that researchers will present 12 abstracts from its respiratory infirmity
program at the 2008 European Respiratory Society Congress (ERS) being held
in Berlin from the 4th to the 8th October. The ERS brings together tons of
the world’s crop respiratory researchers and clinicians to hear latest
advances in clinical diagnosis and treatment.

A comprehensive program of research liking be presented in ERS symposiums
and broadsheet sessions relating to the lung challenge product, Aridol, and the
mucus clearing agent, Bronchitol.

In a poster meeting Professor Di Bilton, Counsellor Physician and
Title only Higher- ranking Lecturer at the Rest on of Respiratory Medicine, The
Royal Brompton Hospital, London, UK, will list results of a successful
randomized, placebo- controlled trial of inhaled mannitol (Bronchitol) in
patients with bronchiectasis.

Other tonality ERS program events from the Pharmaxis respiratory disease
program include:

— The take of inhaled mannitol (Aridol) also in behalf of assessing airway disease
— Direct versus indirect airway challenges
— Using a dry capability of mannitol (Aridol) versus methacholine as
take exception to representing routine practice
— Inhaled mannitol (Bronchitol) as treatment for children with cystic
Fibrosis
— Implications for everyday practice
— Infectious lung diseases including tuberculosis
— A randomized, placebo-controlled provisional of inhaled
mannitol(Bronchitol) in patients with bronchiectasis
— Cough and airway hyperresponsiveness
— A comparison of inhaled mannitol (Aridol), methacholine
provocation and eucapnic free hyperventilation as diagnostic
tests for exercised-induced bronchoconstriction in angry country
skiers
— Assessment of inflammation, hyperresponsiveness and response to
put to use in asthmatic children
— Mannitol shrivel powder provocation (Aridol) in balancing with employ
testing and methacholine call into test in children
— Responsiveness to mannitol (Aridol) and exercise ultimatum in
children with asthma
— Combine between mannitol uninteresting powder confrontation (Aridol) test
results and fractional exhaled nitric oxide in children
— Exercise-induced asthma, acute strait-laced asthma and allergic rhinitis in
Children

tadalafil

— Change of drilling challenge tests and mannitol challenge assess
(Aridol) during optimized asthma treatment in adolescents with
exercise induced asthma
— Investigation, inspiration, ventilation, pledge: the soul of
physiological measurement
— The perception of breathlessness during bronchoconstriction induced
by mannitol (Aridol) in COPD
— Phenotyping of asthma and COPD
— Airway hyperresponsiveness to mannitol (Aridol) and exhaled NO are
interconnected to inflammatory subtypes in asthma.

ERS is Europe’s biggest annual well-ordered get-together in respiratory
medicine, with more than 17,000 participants each year. It aims to provide
a platform for important improvements in the treatment of lung diseases.
Brilliant details of ERS may be viewed on the ERS website at
http://dev.ersnet.org/415-general-information.htm

The statements contained in this media release that are not purely
historical are forward-looking statements within the purport of Section 21E
of the Securities Exchange Act of 1934, as amended. Remit-looking
statements in this media release tabulate statements regarding our
expectations, beliefs, hopes, goals, intentions, initiatives or strategies,
including statements regarding the imminent in requital for Aridol and/or Bronchitol.
All forward-looking statements included in this media release are based
upon information available to us as of the passe hereof, and we assume no
obligation to update any such impertinent-looking statement as a be produced end of new
information, future events or otherwise. We can not guarantee that any
product candidate will receive FDA or other regulatory give the stamp of approval to or that we
whim seek any such approval. Factors that could cause or bestow to such
differences include, but are not limited to, factors discussed in the “Risk
Factors and Other Uncertainties” leg of our Stamp 20-F lodged with the
U.S. Securities and Exchange Commission.

Pharmaxis

February 20, 2010

Radiation Protection Drug Shows Promise In Animal Tests

Filed under: Uncategorized — votessheila @ 7:28 am

Scientists in the US have developed a drug that protected laboratory mice and monkeys from radiation damage and may one heyday be used to protect people
from the side effects of dispersal used in medical procedures such as cancer treatments, and even the effects of nuclear weapons.

A inquiry describing the laboratory findings is published today, 11th April, in the early online issue of Subject and is the work of investigators from
the Roswell Park Cancer Institute and Cleveland BioLabs, Inc, both in Buffalo, Revitalized York; supplementary the Lerner Fact-finding Institute at the Cleveland Clinic in Ohio,
and the Burnham Institute for Medical Fact-finding in La Jolla, California.

Exposure to dispersal causes cells to commit suicide by triggering programmed chamber decease or apoptosis. However, tumour cells have a course of action of stopping
apoptosis, which is why cancer cells proliferate.

Cleveland BioLabs developed an experimental sedate called CBLB502 to prompt the signalling mechanism Euphemistic pre-owned by tumour cells to hold in check apoptosis to see if it
could protect healthy cells from radiation harm.

CBLB502 is a polypeptide derived from the whip like tails of the Salmonella bacterium and it binds to a cubicle receptor called TLR5 to trigger appropriate
apoptosis-suppressing signal.

In the course of this study, the scientists gave laboratory mice a single injection of CBLB502 and then exposed them to a lethal amount body dose of emanation.

The drug protected the mice against the effects of radiation on organs of the digestive tract and in blood apartment producing bone marrow (protected against “gastrointestinal and
hematopoietic acute radiation syndromes”) and improved their survival.

Other mice that were injected after being irradiated also survived longer, but only at diminish doses of radiation.

Similar effects were demonstrated in rhesus monkeys, with 90 per cent of lethally irradiated monkeys surviving after three weeks compared with 20 per cent of
the controls.

The scientists concluded that:

“TLR5 agonists could potentially renovate the health-giving ratio of cancer radiotherapy and be of assistance as biological protectants in radiation emergencies.”

Pattern week, on 3rd April, the US Department of Defense awarded Cleveland BioLabs an 8.9 million dollar preliminary contract
to show CBLB502 as a “Medical Emanation Countermeasure to treat radiation injury following revelation to radiation from atomic or radiological
weapons.”

The corporation is developing another series of drugs called CBLB600, which stimulate the immune system. These could be cast-off with CBLB502 to protect against
diffusion injure (which also affects the unsusceptible system) or on its own to reduce the side effects of chemotherapy.

They are also exploring the exigency execrate of CBLB600 as a in work to produce stem cells after discovering that the add to increases numbers of hematopoietic stem cells
(HSC) in both the bone marrow and peripheral blood.

“An Agonist of Toll-In the mood for Receptor 5 Has Radioprotective Activity in Mouse and Primate Models.”
Lyudmila G. Burdelya, Vadim I. Krivokrysenko, Thomas C. Tallant, Evguenia Strom, Anatoly S. Gleiberman, Damodar Gupta, Oleg V. Kurnasov, Farrel L. Fort,
Andrei L. Osterman, Joseph A. DiDonato, Elena Feinstein, and Andrei V. Gudkov.

Tadalafil

Science 11 April 2008, Vol. 320. no. 5873, pp. 226 - 230.
DOI: 10.1126/science.1154986.

Click here as regards Abstract.

Sources: Journal Ideational, Cleveland BioLabs.

Written by: Catharine Paddock, PhD

Copyright: Medical News Today

Not to be reproduced without permission of Medical Dirt Today

Older Posts »

Powered by WordPress